On Dec. 8, 2021, the Food and Drug Administration (FDA) authorized AstraZeneca’s Evusheld under emergency use for prevention of COVID-19 infection in certain adults and children. Evusheld is a long-acting monoclonal antibody therapy.
Our children are back in school, the COVID-19 pandemic is still here, flu season is upon us, and the common cold never goes away. In addition, the Centers for Disease Control and Prevention (CDC) warned this year about the rise of respiratory syncytial virus (RSV), a virus that is most severe in children under age two but can infect school-aged children.
Getting diagnosed with COVID-19 can be scary. However, in addition to the safe and effective vaccines, we now have more treatments available that can reduce the severity of COVID-19 in those who have become infected. Monoclonal antibody (mAb) treatments have the potential to save lives and relieve the burden on Oregon’s health care system and […]